CAS: 37669-78-6; Ethyl 2,4-Dimethylnicotinate

该化合物是一种丙烯衍生物,分子式为C10H13NO2,其分子式为C10H13NO2,在2和4位置的3位置和甲基替代组中有一个碳箱酸酯酯组,该化合物是有机合成的多种中间体,特别是在制备药品,农用化学品和精细化学品方面,其结构特征增强了核循环和电益替代反应的再活性,对构建复杂的七环框架很有价值.乙酯组提高了有机溶剂的溶性,促进了下游的修改.根据明确的纯度和稳定性特征,该化合物适合于需要精确地将基于丙烯的鱼叉化物转化为功能的研究和工业应用.

结构式图片

相似化合物

55314-30-2 194151-96-7 168072-32-0

物理性质

MSDS等安全信息

上下游产品

2,4-dimethyl-1,4-dihydro-pyridine-3-carboxylic acid ethyl ester 1-amino-1-buten-3-one ethyl acetoacetate 2,4,6-Trimethyl-[1,3,5]triazinane; hydrate3-Acetyl-2,4-dimethylpyridin 2,4-dimethylnicotinic acid (2,4-dimethylpyridin-3-yl)-methanol 4,4',6,6'-tetramethyl-5,5'-bis[(S)-(-)-1-phenylethylcarbamoyl]-2,2'-bipyridine

合成工艺路线路线简述

    📜3-氨基巴豆酸乙酯置于哌啶,Ammonium Cerium(Iv) Nitrate体系中,用 乙醇,丙酮 作为反应溶剂,化学反应 3.33H,反应生成 乙基2,4-二甲基吡啶-3-羧化物
    参考文献:非肽血管紧张素ii受体拮抗剂.i.吡啶衍生物的合成和生物活性.
    标题:非肽血管紧张素ii受体拮抗剂.i.吡啶衍生物的合成和生物活性.
    摘要:取代的吡啶被合成为潜在的血管紧张素ii(aii)受体拮抗剂.在吡啶的2位取代导致有效的活性,并且最佳的烷基长度为四个碳.随着在位置4处引入羟甲基的影响,效力进一步提高.化合物之一是2-丁基-6-氯-4-氯甲基-4-羟甲基-5-甲基-3-[[2'-(1H-四唑-5)-Yl)联苯基-4-Yl]甲基]吡啶9 H(kt3-579)是竞争性aii拮抗剂,Pa2值为9.31,效力是du Pont 753的约10倍.发现它是at1特异性拮抗剂,Ic50为3.09 Nm.
    DOI:10.1248/cpb.42.1841

    海关参考信息

    专利信息


    专利号:US-6818773-B2
    优先权日:2001-10-15
    标题:Synthesis of 4-[(Z)-4-bromophenyl)(ethoxyimino) methyl]-1'-[(2,4-dimethyl-1-oxido-3-pyridinyl)carbony)]-4'-methyl-1,4-′bipiperidine
    发明人：CHEN MINZHANG; D SA BOSCO ANTHONY; LEONG WILLIAM W; GAN TONG; WONG GEORGE S K; TANG SUHAN; NIELSEN CHRISTOPHER MICHAEL
    权利人:SCHERING CORP
    摘要:In one embodiment, the present invention describes the synthesis of 4-[(Z)-(4-bromophenyl)(ethoxyimino)methyl]-1'-[(2,4-dimethyl-1-oxido-3-pyridinyl)carbonyl]-4'-methyl-1,4'-bipiperidine, and intermediates therefor from easily available starting materials by a simple route.

    专利号:US-6992189-B2
    优先权日:2002-03-29
    标 题 :Synthesis of piperidine and piperazine compounds as CCR5 antagonists
    发明人：LEONG WILLIAM; CHEN MINZHANG; D SA BOSCO A; ZHU MAN; XIAO TONG; SHI XIONGWEI; TANG SUHAN; GALA DINESH; GOODMAN ANDREW J; NIELSEN CHRISTOPHER M; LEE GARY M; GAMBOA JUAN A; JONES ANDREW D
    权利人:SCHERING CORP
    摘要:In its several embodiments, this invention discloses novel processes to prepare the compounds of formula II and formula IV:

    专利号:US-2004024217-A1
    优先权日:2002-03-29
    标题 :Synthesis of piperidine and piperazine compounds as CCR5 antagonists

    专利号:US-10112955-B2
    优先权日:2015-10-29
    标题 :Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2
    发明人：SPRENGELER PAUL A; REICH SIEGFRIED H; ERNST JUSTIN T; WEBBER STEPHEN E; SHAGHAFI MIKE; MURPHY DOUGLAS; TRAN CHINH
    权利人:EFFECTOR THERAPEUTICS INC
    摘要:The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. n nFor Formula I compounds A 1 , A 2 , A 3 , A 4 , A 5 , W 1 , Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6a , R 6b , R 7 , R 8 , R 8a , R 8b , R 9 , R 9a , R 9b , and R 10 and subscript “nâ€? are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

    专利号:JP-2005521743-A
    优先权日:2002-03-29
    标 题 :Synthesis of piperidine and piperazine compounds as CCR5 antagonists

    专利号:US-2005187248-A1
    优先权日:2002-03-29
    标题 :Synthesis of piperidine and piperazine compounds as CCR5 antagonists

    其他信息查阅

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    实用工具

    ⚠️全国化工行业净网倡议书
    📋制造商识别码
    📖 海关编码查询
    📝MSDS生成器

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献

    合成方法参考DOI号:10.1021/acs.orglett.6b02883
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知